2026 Q2 - tulosraportti
43 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 | ||
| 33 251 | ||
| 376 | ||
| 492 | ||
| 3 523 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 23.9. | ||
2026 Q1 - tulosraportti 24.6. | ||
2025 Q4 - tulosraportti 25.3. | ||
2025 Q3 - tulosraportti 26.11.2025 | ||
2025 Q2 - tulosraportti 17.9.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·8 t sitten · MuokattuDIANA is NATO's innovation program, which provides companies with funding, testing opportunities, and contact with military users to develop technology with civilian and military utility. SoftOx has a particularly good thematic match with the 2027 cohort "Human Survivability": treatment near the point of care and medical countermeasures when evacuation and supplies are difficult. SIS is already being developed as an inhaled biological countermeasure through EDF/COUNTERACT. A possible compact activation pack would also fit the need for practical preparedness and field use. F أما FFI connection makes the track extra interesting. SoftOx has already collaborated with FFI on both technology and the EDF application, while FFI's ICE Worx - an arena for testing and development together with industry and the Norwegian Armed Forces - has been registered as a test center in the DIANA network. This provides a concrete interface for guidance and testing, even though it does not mean automatic admission. Much of the application basis is thus already in place. Admission provides €100,000 in contract funding without giving up equity, but the network and testing opportunities may be even more important. Application is not confirmed, but this appears to be a very low-hanging fruit I would be surprised if they had not considered thoroughly picking. The deadline was July 3, and the announcement of the 2027 cohort is expected in December, prior to start-up in January. [Source: DIANA application](https://iuk-business-connect.org.uk/opportunities/nato-defence-innovation-accelerator-diana-2027-cohort)
- ·1 päivä sittenMarket-moving alert — SOFTX 🔬 WIAB patent watch — material change • EP4178360A1 [epo] new family publication: CN122999044A What has happened: The subsidiary WIAB (Water Innovation AB) had a Chinese divisional application published on October 30 with independent claims for the multi-chamber container itself (claim 1) and the method for preparing an inhalation formulation (claim 16). While the parent application in China had independent claims directed at the formulations themselves, the divisional seeks protection for a solution where the components (such as a precursor with calcium hypochlorite and acetic acid) are stored in separate chambers and combined right before use. Why it is interesting (Civil clinic and military field product): By separating storage from preparation, one can solve challenges regarding the long-term storage of ready-to-use hypochlorous acid-based inhalation solution. This can provide significantly better shelf life, simpler transport, less waste, and a more standardized preparation. Speculation regarding military product: These characteristics hit the bullseye on the requirements in the defense and preparedness track (EDF/COUNTERACT and the phase 1 study SIS-02 under SoftOx Defense Solutions AS), where SIS is being developed as a countermeasure against biological threats for the defense sector. In emergency stockpiles and out in the field, one depends on long storage time and rapid, secure activation when needed – something a closed multi-chamber/single-use container directly facilitates. The significance of the China track: Although the multi-chamber architecture is already known from the WO and US applications in the family, this demonstrates active portfolio building to protect the value chain: 1. Protection of the consumable segment: WIAB is seeking protection around the container and preparation, in addition to the formulation. This can provide control over a protected single-use container/consumable and a recurring delivery model – even if the nebulizer itself comes from a third party. 2. Preventing copying: European and American patents do not automatically provide protection in China. Separate claims on the container make it harder to produce and sell local copies of the consumable part. 3. Partner and production flexibility: If relevant claims are granted and the solution is used in SIS, it strengthens the overall package toward future licensing, production, and partner agreements by covering both important sales markets and potential production countries.Yash, WIAB has already been granted the multi-chamber solution and other patents in the USA, so let us hope the Chinese also find something to like. Allowed to be a little optimistic, right?
- ·2 päivää sittenBottom reached, upturn on the way?
Quite unpredictable I think. I have both buy and sell orders in. Placing a sell at 0.135 in case it gets pumped from Dichesbuen. If not then I think it will go down. he still has 58 mill shares. Sold 4mill 28/10 price approx 0.11. I don't think he manages to pump much over 0.13 which is the latest issue price. Six sis is sitting on a lot of shares at that price and will likely sell right above it - ·3 päivää sitten · MuokattuAnalyst Group believes the stock is worth 0.2 kr today. The apes in here believe it should be declared bankrupt today. Oslo Børs has become a casino without substance .
That was a strange statement. Who says the company should be filed for bankruptcy today? A company with incredible potential just waiting to be unlocked...., pretty sure the company will be valued above 1 kr per share when we write Q2-2027...., that is just my opinion then.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
43 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·8 t sitten · MuokattuDIANA is NATO's innovation program, which provides companies with funding, testing opportunities, and contact with military users to develop technology with civilian and military utility. SoftOx has a particularly good thematic match with the 2027 cohort "Human Survivability": treatment near the point of care and medical countermeasures when evacuation and supplies are difficult. SIS is already being developed as an inhaled biological countermeasure through EDF/COUNTERACT. A possible compact activation pack would also fit the need for practical preparedness and field use. F أما FFI connection makes the track extra interesting. SoftOx has already collaborated with FFI on both technology and the EDF application, while FFI's ICE Worx - an arena for testing and development together with industry and the Norwegian Armed Forces - has been registered as a test center in the DIANA network. This provides a concrete interface for guidance and testing, even though it does not mean automatic admission. Much of the application basis is thus already in place. Admission provides €100,000 in contract funding without giving up equity, but the network and testing opportunities may be even more important. Application is not confirmed, but this appears to be a very low-hanging fruit I would be surprised if they had not considered thoroughly picking. The deadline was July 3, and the announcement of the 2027 cohort is expected in December, prior to start-up in January. [Source: DIANA application](https://iuk-business-connect.org.uk/opportunities/nato-defence-innovation-accelerator-diana-2027-cohort)
- ·1 päivä sittenMarket-moving alert — SOFTX 🔬 WIAB patent watch — material change • EP4178360A1 [epo] new family publication: CN122999044A What has happened: The subsidiary WIAB (Water Innovation AB) had a Chinese divisional application published on October 30 with independent claims for the multi-chamber container itself (claim 1) and the method for preparing an inhalation formulation (claim 16). While the parent application in China had independent claims directed at the formulations themselves, the divisional seeks protection for a solution where the components (such as a precursor with calcium hypochlorite and acetic acid) are stored in separate chambers and combined right before use. Why it is interesting (Civil clinic and military field product): By separating storage from preparation, one can solve challenges regarding the long-term storage of ready-to-use hypochlorous acid-based inhalation solution. This can provide significantly better shelf life, simpler transport, less waste, and a more standardized preparation. Speculation regarding military product: These characteristics hit the bullseye on the requirements in the defense and preparedness track (EDF/COUNTERACT and the phase 1 study SIS-02 under SoftOx Defense Solutions AS), where SIS is being developed as a countermeasure against biological threats for the defense sector. In emergency stockpiles and out in the field, one depends on long storage time and rapid, secure activation when needed – something a closed multi-chamber/single-use container directly facilitates. The significance of the China track: Although the multi-chamber architecture is already known from the WO and US applications in the family, this demonstrates active portfolio building to protect the value chain: 1. Protection of the consumable segment: WIAB is seeking protection around the container and preparation, in addition to the formulation. This can provide control over a protected single-use container/consumable and a recurring delivery model – even if the nebulizer itself comes from a third party. 2. Preventing copying: European and American patents do not automatically provide protection in China. Separate claims on the container make it harder to produce and sell local copies of the consumable part. 3. Partner and production flexibility: If relevant claims are granted and the solution is used in SIS, it strengthens the overall package toward future licensing, production, and partner agreements by covering both important sales markets and potential production countries.Yash, WIAB has already been granted the multi-chamber solution and other patents in the USA, so let us hope the Chinese also find something to like. Allowed to be a little optimistic, right?
- ·2 päivää sittenBottom reached, upturn on the way?Quite unpredictable I think. I have both buy and sell orders in. Placing a sell at 0.135 in case it gets pumped from Dichesbuen. If not then I think it will go down. he still has 58 mill shares. Sold 4mill 28/10 price approx 0.11. I don't think he manages to pump much over 0.13 which is the latest issue price. Six sis is sitting on a lot of shares at that price and will likely sell right above it
- ·3 päivää sitten · MuokattuAnalyst Group believes the stock is worth 0.2 kr today. The apes in here believe it should be declared bankrupt today. Oslo Børs has become a casino without substance .That was a strange statement. Who says the company should be filed for bankruptcy today? A company with incredible potential just waiting to be unlocked...., pretty sure the company will be valued above 1 kr per share when we write Q2-2027...., that is just my opinion then.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 | ||
| 33 251 | ||
| 376 | ||
| 492 | ||
| 3 523 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 23.9. | ||
2026 Q1 - tulosraportti 24.6. | ||
2025 Q4 - tulosraportti 25.3. | ||
2025 Q3 - tulosraportti 26.11.2025 | ||
2025 Q2 - tulosraportti 17.9.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
43 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 23.9. | ||
2026 Q1 - tulosraportti 24.6. | ||
2025 Q4 - tulosraportti 25.3. | ||
2025 Q3 - tulosraportti 26.11.2025 | ||
2025 Q2 - tulosraportti 17.9.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·8 t sitten · MuokattuDIANA is NATO's innovation program, which provides companies with funding, testing opportunities, and contact with military users to develop technology with civilian and military utility. SoftOx has a particularly good thematic match with the 2027 cohort "Human Survivability": treatment near the point of care and medical countermeasures when evacuation and supplies are difficult. SIS is already being developed as an inhaled biological countermeasure through EDF/COUNTERACT. A possible compact activation pack would also fit the need for practical preparedness and field use. F أما FFI connection makes the track extra interesting. SoftOx has already collaborated with FFI on both technology and the EDF application, while FFI's ICE Worx - an arena for testing and development together with industry and the Norwegian Armed Forces - has been registered as a test center in the DIANA network. This provides a concrete interface for guidance and testing, even though it does not mean automatic admission. Much of the application basis is thus already in place. Admission provides €100,000 in contract funding without giving up equity, but the network and testing opportunities may be even more important. Application is not confirmed, but this appears to be a very low-hanging fruit I would be surprised if they had not considered thoroughly picking. The deadline was July 3, and the announcement of the 2027 cohort is expected in December, prior to start-up in January. [Source: DIANA application](https://iuk-business-connect.org.uk/opportunities/nato-defence-innovation-accelerator-diana-2027-cohort)
- ·1 päivä sittenMarket-moving alert — SOFTX 🔬 WIAB patent watch — material change • EP4178360A1 [epo] new family publication: CN122999044A What has happened: The subsidiary WIAB (Water Innovation AB) had a Chinese divisional application published on October 30 with independent claims for the multi-chamber container itself (claim 1) and the method for preparing an inhalation formulation (claim 16). While the parent application in China had independent claims directed at the formulations themselves, the divisional seeks protection for a solution where the components (such as a precursor with calcium hypochlorite and acetic acid) are stored in separate chambers and combined right before use. Why it is interesting (Civil clinic and military field product): By separating storage from preparation, one can solve challenges regarding the long-term storage of ready-to-use hypochlorous acid-based inhalation solution. This can provide significantly better shelf life, simpler transport, less waste, and a more standardized preparation. Speculation regarding military product: These characteristics hit the bullseye on the requirements in the defense and preparedness track (EDF/COUNTERACT and the phase 1 study SIS-02 under SoftOx Defense Solutions AS), where SIS is being developed as a countermeasure against biological threats for the defense sector. In emergency stockpiles and out in the field, one depends on long storage time and rapid, secure activation when needed – something a closed multi-chamber/single-use container directly facilitates. The significance of the China track: Although the multi-chamber architecture is already known from the WO and US applications in the family, this demonstrates active portfolio building to protect the value chain: 1. Protection of the consumable segment: WIAB is seeking protection around the container and preparation, in addition to the formulation. This can provide control over a protected single-use container/consumable and a recurring delivery model – even if the nebulizer itself comes from a third party. 2. Preventing copying: European and American patents do not automatically provide protection in China. Separate claims on the container make it harder to produce and sell local copies of the consumable part. 3. Partner and production flexibility: If relevant claims are granted and the solution is used in SIS, it strengthens the overall package toward future licensing, production, and partner agreements by covering both important sales markets and potential production countries.Yash, WIAB has already been granted the multi-chamber solution and other patents in the USA, so let us hope the Chinese also find something to like. Allowed to be a little optimistic, right?
- ·2 päivää sittenBottom reached, upturn on the way?Quite unpredictable I think. I have both buy and sell orders in. Placing a sell at 0.135 in case it gets pumped from Dichesbuen. If not then I think it will go down. he still has 58 mill shares. Sold 4mill 28/10 price approx 0.11. I don't think he manages to pump much over 0.13 which is the latest issue price. Six sis is sitting on a lot of shares at that price and will likely sell right above it
- ·3 päivää sitten · MuokattuAnalyst Group believes the stock is worth 0.2 kr today. The apes in here believe it should be declared bankrupt today. Oslo Børs has become a casino without substance .That was a strange statement. Who says the company should be filed for bankruptcy today? A company with incredible potential just waiting to be unlocked...., pretty sure the company will be valued above 1 kr per share when we write Q2-2027...., that is just my opinion then.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 | ||
| 33 251 | ||
| 376 | ||
| 492 | ||
| 3 523 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt